# A Study of the Immunogenicity, Tolerability, and Safety of a New Formulation of RotaTeq™ in Infants (V260-035)

> **NCT01600092** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 1020 (actual)

## Conditions studied

- Rotavirus Gastroenteritis

## Interventions

- **BIOLOGICAL:** RotaTeq™ experimental formulation
- **BIOLOGICAL:** RotaTeq™ existing formulation

## Key facts

- **NCT ID:** NCT01600092
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04-29
- **Primary completion:** 2014-03-25
- **Final completion:** 2014-03-25
- **Target enrollment:** 1020 (ACTUAL)
- **Last updated:** 2018-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01600092

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01600092, "A Study of the Immunogenicity, Tolerability, and Safety of a New Formulation of RotaTeq™ in Infants (V260-035)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01600092. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*